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PATHOGENIC mtDNA MUTATIONS CAUSING
MITOCHONDRIAL MYOPATHY: THE NEED FOR
MUSCLE BIOPSY
Pathogenic mitochondrial tRNA (mt-tRNA) gene
mutations represent a prominent cause of primary
mitochondrial DNA (mtDNA)-related disease
despite accounting for only 5%–10% of the mito-
chondrial genome.1,2 Although some common
mt-tRNA mutations, such as the m.3243A.G
mutation, exist, the majority are rare and have
been reported in only a small number of cases.3
The MT-TP gene, encoding mt-tRNAPro, is one
of the less polymorphic mt-tRNA genes, and only
5 MT-TP mutations have been reported as a cause
of mitochondrial muscle disease to date (table e-1
at Neurology.org/ng, P6–10). We report 5 pa-
tients with myopathic phenotypes, each harboring
different pathogenic mutations in the MT-TP gene,
highlighting the importance of MT-TP mutations as
a cause of mitochondrial muscle disease and the
requirement to study clinically relevant tissue.
Methods. All patients were referred to our special-
ist mitochondrial laboratory in Newcastle upon
Tyne, UK. Diagnostic muscle biopsies were ana-
lyzed by standard histopathologic and biochemical
techniques and a quadruple immunofluorescent
assay to assess the expression of mitochondrial
complex I and complex IV subunits.4 DNA was
extracted using standard protocols; sequencing of
the entire mitochondrial genome (GenBank
Accession Number NC_012920.1) was under-
taken using muscle DNA. Pyrosequencing was
used to quantitatively assess mtDNA mutation
heteroplasmy levels in available tissues and in
laser-captured individual cytochrome c oxidase
(COX)-positive and COX-deficient fibers.2
Results. We identified 5 adult patients with mito-
chondrial disease due to mutations in the MT-TP
gene; their clinical, histochemical, and genetic data
are summarized in table e-1. Histopathologic analysis
of muscle biopsies from all 5 patients revealed marked
mitochondrial pathology in the form of a mosaic pat-
tern of COX deficiency (figure 1A), which ranged
from ;16% COX-deficient fibers in patient 3 up
to .80% COX-deficient fibers from patients 2 and
5. COX-deficient ragged-red fibers were noted in all
patients to varying degrees, although strongly succinate
dehydrogenase–reactive blood vessels were not
reported (figure 1A). Quantitative fluorescence-based
immunohistochemistry confirmed decreased levels of
both complex I (NDUFB8) and complex IV (COX-I)
subunits, in accordance with an underlying disorder of
mitochondrial translation (figure e-1).
Sequencing of the entire mitochondrial genome
identified candidate MT-TP gene mutations at evolu-
tionarily conserved positions in all 5 patients (figure 1,
A and B; figure e-2). The m.15975T.C mutation5
and m.16002T.C mutation6 in patients 1 and 3,
respectively, were previously reported, while those in
patient 2 (m.15998A.T), patient 4 (m.16015T.C),
and patient 5 (m.16021_16022del) were novel. In all
cases, the highest mutation load was detectable in
muscle, varying from 25% in patient 3 to .95% in
patients 2 and 5 (table e-1). Screening of additional
tissues was also performed; patients 1, 2, and 3 showed
restricted expression of the MT-TP mutation to mus-
cle, while patients 4 and 5 showed a hierarchical muta-
tion segregation pattern (table e-1). Single muscle
fiber segregation studies demonstrated statistically sig-
nificant higher mutation levels in COX-deficient fi-
bers compared with COX-positive fibers, thus
confirming pathogenicity of each MT-TP mutation
(figure 1C; table e-2).
Discussion. We report 5 adult patients with mito-
chondrial disease due to different mutations in the
MT-TP gene with a predominantly myopathic pheno-
type. Ptosis (1/2 progressive external ophthalmople-
gia), proximal myopathy, and marked perceived
fatigue appear to be salient features. In each case, the
marked degree of COX deficiency and downregulation
of both complex I and complex IV subunits in muscle
was strongly suggestive of a defect in mitochondrial
translation and entirely in keeping with an mt-tRNA
mutation. To date, only 5 patients have been reported,
each with different MT-TP mutations, and variable
clinical features have been observed including ataxia,
deafness, dilated cardiomyopathy, myoclonic epilepsy
with ragged-red fibers–like disease, and retinitis
pigmentosa; a myopathic phenotype is reported in all
cases (table e-1).
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Patients 1, 2, and 3 showed restricted expression of
their MT-TP mutations to muscle, strongly indicative
of a de novo mutational event,7 whereas patients 4 and
5 showed a hierarchical segregation pattern as observed
in many pathogenic mtDNA mutations. Screening of
maternal samples was undertaken for patients 2, 4, and
5, with maternal inheritance being confirmed in
patient 4 only. Of note, only one of the previous stud-
ies demonstrated maternal inheritance of the MT-TP
mutation, with 4 of the remaining studies also report-
ing apparent or likely de novo mutational events.
Single muscle fiber segregation studies remain
the gold standard test to confidently establish patho-
genicity of novel mtDNA variants. Although the
m.15975T.C5 and m.16002T.C6 mutations have
been reported previously, functional studies were not
undertaken to confirm pathogenicity. Subsequent
studies in muscle biopsies of all 5 patients confirm
that mutation loads segregated with the mitochon-
drial histochemical defects in muscle (figure 1C; table
e-2), powerfully illustrating an ongoing requirement
to access pathologically relevant tissue—skeletal
muscle—to support the investigation and diagnosis
of patients with mitochondrial myopathy, even in the
current era of high-throughput next-generation
sequencing technologies.
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Figure 1 Histopathologic and molecular genetic characterization of 5 pathogenic MT-TP (mt-tRNAPro) mutations
(A) Sequential COX-succinate dehydrogenase histochemistry demonstrating a mosaic pattern of COX deficiency in all patient muscle samples (COX-defi-
cient fibers are blue, COX-positive fibers are brown); note the presence of COX-deficient ragged-red fibers in each of the 5 biopsies (scale bar 5
100 mm). Sequence electropherograms showing the relevant MT-TP mutation for each patient are also included. (B) Schematic representation of the
cloverleaf structure of the mt-tRNAPro molecule and the corresponding location of the 5 pathogenic mutations. Each mutation occurs in a different stem
of the mt-tRNAPro molecule. The affected position and the substitution that occurs are highlighted in bold. (C) Single muscle fiber mutation load segregation.
The graph shows the mutation load measured in individual COX-positive (closed circles) and COX-deficient fibers (open circles) laser-microdissected from
muscle biopsies of the 5 patients. In each case, the candidate MT-TP mutation segregates with the biochemical (COX) defect in single muscle fibers.
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